ms 21

MS21 is a unique AKT degrader that selectively hampers the proliferation of cancers with mutations in the PI3K/PTEN pathway, alongside wild-type KRAS and BRAF.

BMS 214428 is a bio-active chemical.

BMS-214662是一种选择性的 farnesyl transferase 抑制剂，具有抗肿瘤活性，可用于研究胰腺癌、头颈癌和肺癌。

BMS-212122 (UNII-0Z473OO6GB) 是一种有效的微粒体甘油三酯转移蛋白(MTP )抑制剂，在动物实验中显示出降血脂作用。BMS-212122 显著减少动脉粥样硬化斑块中的脂质含量和单核细胞衍生(CD68+)细胞。

(±)-Naringenin (Naringenine) 是一种天然的类黄酮。它通过激活肌细胞中 BKCa 通道发挥对内皮剥脱血管的舒张作用。

trans-Zeatin ((E)-Zeatin) 是植物细胞分裂素，可抑制紫外线诱导的MEK/ERK 的活化，在细胞生长、分化和分裂中起着重要的作用。

IMS2186 是一种抗脉络膜新生血管 (CNV) 试剂， 可以使癌细胞周期阻滞在 G2/M 期，由此产生抗增殖和抗血管生成作用。IMS2186 能够减少眼睛渗漏和病变细胞的数量，并且无眼内毒性。

BMS-214662 mesylate 是一种高效且选择性的farnesyl transferase抑制剂，IC50值为1.35 nM，并且展现出抗肿瘤活性，适用于癌症研究。

MS2133 是一种 DOT1L PROTAC 降解剂，能够促进 THP-1 和 MV4-11 细胞中 DOT1L 的泛素化和降解 (DC50分别为: 56 nM 和 25 nM)，并降低 H3K79 甲基化水平。MS2133 对 MLL-r 白血病细胞的生长具有抑制作用，展现出抗癌活性。

MS2126 is a Human p53 and CREB Binding Protein interaction inhibitor.

MS2177 is a potent and selective inhibitor of SETD8, the only methyltransferase known to catalyze monomethylation of histone H4 lysine 20 (H4K20). MS2177 has an in vitro IC50 of 1.9 μM (σ = 1.05 μM, n = 4) in ascintillation proximity assay. Binding of MS2

BMS-210285 is a bio-active chemical.

Tasimelteon (BMS-214778) 是一种褪黑激素受体激动剂，用于治疗盲人的非 24 小时睡眠-觉醒障碍。

MS21570 作为 GPR171 拮抗剂基于其阻断能力，IC50 为 220 nM，可减少小鼠的焦虑样行为和恐惧条件反射。

BMS-214662 hydrochloride is a Farnesyltransferase inhibitor , is also a nonsedating benzodiazepine derivative with potential antineoplastic activity. BMS-214662 hydrochloride inhibits the enzyme farnesyltransferase and the post-translational farnesylation of number of proteins involved in signal transduction, which may result in the inhibition of Ras function and apoptosis in susceptible tumor cells. This agent may reverse the malignant phenotype of H-Ras-transformed cells and has been shown to be active against tumor cells with and without Ras mutations.

Dehatrine is from an Indonesian medical plant Beilschmiedia madang; a bisbibenzylisoquinoline alkaloid; inhibits growth of cultured Plasmodium falciparum K1 strain.

Zeaxanthin 是聚在视网膜（特别是黄斑）中的膳食类胡萝卜素，具有抗氧化活性，可以改善肥胖，预防与年龄相关的黄斑变性，并预防非酒精性脂肪性肝炎。

trans-Zeatinriboside (Ribosylzeatin) 是一种细胞分裂素前体，是木质素导管中主要的长距离信号形式，能够调节叶片大小和分生组织活性相关形状。

Flumequine-13C3 is intended for use as an internal standard for the quantification of flumequine by GC- or LC-MS. Flumequine (T1060) is a fluoroquinolone antibiotic.1It is active againstS. aureus,S. pyogenes,B. subtilis,E. coli,P. aeruginosa,S. faecalis,andK. pneumoniae (MICs = 1-100 μg/ml). Flumequine (T1060) is also active against field isolates of B. hyodysenteriae (MICs = 6.25-200 μg/ml).2It inhibits DNA gyrase,disrupting supercoiling of bacterial DNA to block transcription and replication.3

Rasagiline-13C3 (mesylate) is intended for use as an internal standard for the quantification of rasagiline by GC- or LC-MS. Rasagiline is an inhibitor of monoamine oxidase B (MAO-B; IC50= 4.43 nM for the rat brain enzyme).1It is selective for MAO-B over MAO-A (IC50= 412 nM for the rat brain enzyme). It inhibits serum and NGF withdrawal-induced apoptosis of PC12 cells when used at concentrations ranging from 0.01 to 100 μM.2Rasagiline inhibits rat brain MAO-Bin vivo (ED50= 0.1 mg/kg).1It reduces cerebral edema in a mouse model of traumatic brain injury.2Rasagiline (0.1 mg/kg)reduces cortical and hippocampal levels of full-length and soluble amyloid precursor protein (APP)in rats and mice. It also reduces α-synuclein-induced substantia nigral neuron loss and improves motor dysfunction in a mouse model of Parkinson's disease.3Formulations containing rasagiline have been used in the treatment of Parkinson's disease.

Zonisamide-13C2,15N is intended for use as an internal standard for the quantification of zonisamide by GC- or LC-MS. Zonisamide (T0267) is an antiepileptic agent.1 It selectively inhibits the repeated firing of sodium channels (IC50 = 2 μg/ml)in mouse embryo spinal cord neurons and inhibits spontaneous channel firing when used at concentrations greater than 10 μg/ml.2 In rat cerebral cortex neurons,zonisamide (1-1,000 μM)inhibits T-type calcium channels with a maximum reduction of 60% of the calcium current.3 Zonisamide (T0267)inhibits H. pylori recombinant carbonic anhydrase (CA)and the human CA isoforms I,II,and V with Ki values of 218,56,35,and 21 nM,respectively.4,5 In mice,it has anticonvulsant activity against maximal electroshock seizure (MES)and pentylenetetrazole-induced maximal,but not minimal,seizures (ED50s = 19.6,9.3,and >500 mg/kg,respectively). Zonisamide (T0267) (40 mg/kg,p.o.)prevents MPTP-induced decreases in the levels of dopamine ,but not homovanillic acid or dihydroxyphenyl acetic acid ,and increases MPTP-induced decreases in the dopamine turnover rate in mouse striatum in a model of Parkinson's disease.6 Formulations containing zonisamide have been used in the treatment of partial seizures in adults with epilepsy.